Anakinra
[대역어] 아나키라
[용어속성] Drug
[용어속성] Drug
Case Report: Case Series of Children With Multisystem Inflammatory Syndrome Following SARS-CoV-2 Infection in Switzerland
Pediatrics
[키워드] addition
Anakinra
anti-IL6
Anti-inflammatory
benefit
case sery
Child
children
clinical feature
Cohort
country
cytokine profile
Cytokine storm
defined
dose
Evidence
Evolution
Hyperinflammatory
IL-1
IL-1ra
IL-6
IL-6 blocking
Immunoglobulin
immunomodulator
Incomplete
Inflammatory
Intravenous immunoglobulin
Laboratory
medication
MIS-C
one patient
overlap
pandemic
Patient
presenting
recent
reported
SARS-CoV-2
SARS-CoV2
Serum level
Sery
severe SARS-CoV-2
steroid
steroid treatment
Switzerland
syndrome
tested
therapy
toxic
TSS
[DOI] 10.3389/fped.2020.594127 PMC 바로가기 [Article Type] Pediatrics
[DOI] 10.3389/fped.2020.594127 PMC 바로가기 [Article Type] Pediatrics
Immunopathogenesis and treatment of cytokine storm in COVID-19
COVID-19에서 면역 병인 및 사이토 카인 폭풍의 치료
Review
[키워드] acute respiratory distress
acute respiratory distress syndrome
addition
Anakinra
Anti-inflammatory therapy
anti-inflammatory treatment
anti-inflammatory treatments
approach
Baricitinib
caused
characterized
clinical condition
clinical conditions
clinical evidence
comparison
Comparisons
conducted
coronavirus
coronavirus disease
Coronavirus disease 2019
COVID-19
COVID-19 cytokine storm
COVID-19 infection
cytokine
cytokine blockades
Cytokine release syndrome
cytokine removal
Cytokine storm
Cytokines
drug
early stage
hemophagocytic lymphohistiocytosis
hyper-inflammation
IFN
IL-1
IL-6
immune reaction
indicated
involved
multiple organ failure
Pathogenesis
Patient
plasma exchange
recent
recommendation
respiratory distress
severe coronavirus disease
severe COVID-19
shown
syndrome
systemic hyper-inflammation
the cytokine storm
therapeutic
Therapies
Tocilizumab
treat
Treatment
while
with COVID-19
[DOI] 10.7150/thno.49713 PMC 바로가기 [Article Type] Review
[DOI] 10.7150/thno.49713 PMC 바로가기 [Article Type] Review
Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis
COVID-19 치료를 위한 약리학적 중재의 비교 효능 및 안전성: 체계적인 검토 및 네트워크 메타 분석
Meta-Analysis
[키워드] 1.26
95% CI
95% confidence interval
Admission
aggravation
Alpha
Anakinra
analyses
Analysis
anti-inflammatory agent
anti-inflammatory agents
Asia
assessment
associations
Azithromycin
benefit
Cardiac complications
cardiac safety risk
cardiac safety risks
cardiac-impaired population
cardiac-impaired populations
carried
categories
category
Causality
certainty
clinical
clinical benefit
clinical benefits
Clinical outcome
clinical settings
clinical trial
ClinicalTrials
clinician
Cochrane Library
collected
Combination
Comparative
controlled trials
convalescent plasma
coronavirus disease
Coronavirus disease 2019
Corticosteroid
Corticosteroids
Course
COVID-19
COVID-19 disease
COVID-19 disease course
COVID-19 treatments
CRD42020186527
Critically ill
Critically ill patient
critically ill patients
daclatasvir
dataset
determine
development
disease course
drug
effective
Efficacy and safety
eligibility criteria
eligible
Europe
evaluate
Evidence
evidence of
fatal cardiac complication
fatal cardiac complications
Google Scholar
help
heterogeneous
High-dose
Hospitalization
hospitalized COVID-19 patients
Hydroxychloroquine
ICU
Immunoglobulin
information
intensive care
intensive care unit
interferon
interferon-alpha
Intravenous immunoglobulin
investigated
itolizumab
Ivermectin
IVIG
Level
management
mechanical ventilation
medRxiv
Meta-analysis
Middle East
mild patients
moderate
moderate to severe
moderate/high evidence certainty
Mortality
mortality rate
mortality rates
Network meta-analysis
NMA
non-ICU
non-ICU setting
noncardiac serious adverse events
North America
Numerous
observational studies
observational study
Odds ratio
outcome
Patient
patients hospitalized
pharmacological agent
pharmacological intervention
pharmacological interventions
pharmacological management
plasma
Policy
populations
Potential treatment
potential treatments
progression
PROSPERO
provide
QT prolongation
QT prolongation incidence
Randomized controlled trial
Randomized controlled trials
randomized trial
randomized trials
RCT
RCTs
recommendations
reduce
reduce COVID-19 aggravation
reduce mortality rate
reduced
reflected
registry
Remdesivir
Research
researcher
Result
risk
risk of bia
RoB
RoB2
ROBINS-I framework
searched
self-limiting disease
Serious Adverse Event
Serious Adverse Events
severe COVID-19 patient
severe disease
severe pneumonia
shown
significantly
sofosbuvir
sofosbuvir plus daclatasvir
South America
SSRN
standard care
Study protocol
supported
systematic review
systematic synthesis
Tocilizumab
translated
Treatment
treatment regimen
viral clearance rate
vulnerable population
WHO
WHO International Clinical Trials Registry Platform
[DOI] 10.1371/journal.pmed.1003501 PMC 바로가기 [Article Type] Meta-Analysis
[DOI] 10.1371/journal.pmed.1003501 PMC 바로가기 [Article Type] Meta-Analysis
Anakinra treatment in critically ill COVID-19 patients: a prospective cohort study
Research
[키워드] aligned
Anakinra
Analysis
analyzed
Aspartate aminotransferase
Bilirubin
both groups
Characteristics
circulating cytokine
clinical
clinical feature
Clinical outcome
clinical outcomes
clinical parameter
Clinical sign
Concentration
control group
Coronavirus disease 2019
Corticosteroids
COVID-19
COVID-19 patient
COVID-19 patients
creatinine
criteria
Critical care
Critically ill
Cytokines
decrease
develop
Diseases
Effect
effective
elevated
ferritin
Fever
groups
hyperinflammation
Hyperinflammatory
hyperinflammatory state
ICU
ICU admission
Immunity
inflammatory parameter
interleukin-1 receptor antagonist protein
investigated
mechanical ventilation
mechanically ventilated
median
outcome
parameters
Patient
plasma
procalcitonin
prospective cohort study
Randomized controlled trial
receive
receptor
reducing
Result
SARS-CoV-2
sensitivity analysis
significantly higher
standard care
subset
temperature
treated
Treatment
treatment group
was performed
White blood cell
[DOI] 10.1186/s13054-020-03364-w PMC 바로가기 [Article Type] Research
[DOI] 10.1186/s13054-020-03364-w PMC 바로가기 [Article Type] Research
A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico study
COVID-19 환자의 숙주 혈전 염증 반응 조절에 대한 무작위, 공개, 적응, 개념 증명 임상 시험: DAWn-Antico 연구
Randomized Controlled Trial
[키워드] Activation
adaptive
added
Anakinra
Aprotinin
bradykinin
cellular entry
Clinical improvement
clinical status
clinical trial
Coagulation
Combination
complications
Contact
country
COVID-19
COVID-19 disease
COVID-19 pandemic
D-dimer
defined
develop
Disease progression
dose
drug
effective
EU Clinical Trial
EU Clinical Trials
fibrinolysis
heparin
heparins
high mortality
hospitalized COVID-19 patients
Host
hyperinflammation
ICU
in vitro
incidence
Infection
inflammatory parameters
Inflammatory response
information
inhibitor
inhibitory effect
initial
intensive care
Intervention
investigated
Kallikrein
local inflammatory response
low molecular weight
Low molecular weight heparins
marker
modulate
modulation
multicenter
Open-label
Ordinal Scale
outcome
pathophysiological
pathway
Patient
Primary outcome
Prognostic factor
proof-of-concept clinical trial
Randomized
randomized clinical trial
reached
receptor
receptor antagonist
reduce
regimen
SARS-CoV-2
second wave
severe COVID-19
severe COVID-19 disease
shown
standard thromboprophylaxis
supplementary material
the WHO
Thromboinflammatory response
thrombotic
Thrombotic complications
Thrombotic events
Trial
Trial registration
vaccination
Viral
viral replication
WHO ordinal scale
[DOI] 10.1186/s13063-020-04878-y PMC 바로가기 [Article Type] Randomized Controlled Trial
[DOI] 10.1186/s13063-020-04878-y PMC 바로가기 [Article Type] Randomized Controlled Trial
Covid-19-Associated Pulmonary Aspergillosis: The Other Side of the Coin
Review
[키워드] acute respiratory syndrome
Anakinra
approach
Aryl hydrocarbon receptor
Aspergillus
Asymptomatic
coin
contribute
coronavirus
COVID-19
COVID-19 patients
Critical
disease
dysregulated immune response
fungal infections
Host
Immune homeostasis
immune response
immunomodulatory
Infection
mechanism
morbidity and mortality
occur
Other
pathway
pulmonary
reduce
risk
SARS-CoV-2
secondary bacterial
Secondary infection
side
significantly
susceptibility
the disease
therapeutic
thymosin alpha 1
Treatment
underlie
viral infection
[DOI] 10.3390/vaccines8040713 PMC 바로가기 [Article Type] Review
[DOI] 10.3390/vaccines8040713 PMC 바로가기 [Article Type] Review
Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review
COVID-19에 대한 면역 요법, 항바이러스 요법 또는 둘 다: 체계적인 검토
Article
[키워드] Admission
Anakinra
analysed
Antiviral
antivirals
article
articles
Baricitinib
case reports
Characteristics
Chloroquine
Clinical features
clinical impact
Colchicine
combination therapy
control group
COVID-19
COVID-19 patient
cumulative
Cytokine release syndrome
database
deaths
Dexamethasone
discharge
disease
dysregulation
Efficacy
eligibility criteria
English language
Evidence
exclusion
explain
Favipiravir
first stage
Google Scholar
helping
High-flow oxygen
Hydroxychloroquine
identify
immune
immune dysregulation
immune response
Inclusion
Inconclusive
indicated
Infection
intensive care
intensive care unit
intensive care unit admission
item
itolizumab
large trial
Loading dose
Lopinavir
Lopinavir/ritonavir
management
medRxiv
meta-analyses
Mortality
Open-label
oxygen
Pathogenesis
pathogenesis of COVID-19
pathogenic mechanism
patients
primary end point
PRISMA
Randomised controlled trials
rationale
RCTs
reduced
reduction
Remdesivir
removal
reported
Reporting
requiring high-flow oxygen
retrospective
review
Ritonavir
ruxolitinib
sarilumab
SARS-CoV-2
SARS-COV-2 infection
significantly
siltuximab
supportive therapy
systematic review
systematic reviews
the disease
the SARS-CoV-2
therapeutic
therapeutic agent
Therapeutic approach
therapeutic approaches
therapy
Time to recovery
Tocilizumab
Treatment
treatment of COVID-19 patients
Trial
trials
triggered
USA
was performed
were excluded
[DOI] 10.1007/s40265-020-01421-w PMC 바로가기 [Article Type] Article
[DOI] 10.1007/s40265-020-01421-w PMC 바로가기 [Article Type] Article
High dose subcutaneous Anakinra to treat acute respiratory distress syndrome secondary to cytokine storm syndrome among severely ill COVID-19 patients
중증 코로나19 환자에서 사이토카인 폭풍 증후군에 이차적으로 발생하는 급성 호흡곤란 증후군 치료를 위한 고용량 피하 아나킨라
Article
[키워드] acute respiratory distress
acute respiratory distress syndrome
adverse effect
age
Aminotransferase
Anakinra
ARDS
Cohort
cohort of patient
cohort study
cohorts
Combination
COVID-19
COVID-19 patient
CRP
CSS
Cytokine storm syndrome
D-dimer
develop
distress
dose
elevated
exhibited
exhibiting
ferritin
group
hyperinflammation
hyperinflammatory state
IL-1
IL-6
IL-6 inhibitor
in both group
Infection
Inflammatory
inhibition
initial
intravenous
males
median
multi-organ failure
non-responder
outcome
paO2/fiO2
PaO2/FiO2 ratio
Patient
patients
patients treated
produced
propensity score matching
reduction
Resolution
Respiratory function
respond
SARS-CoV2
severe COVID-19
significantly increased
single dose
Subcutaneous
syndrome
TCZ
therapy
Tocilizumab
treat
treated
Treatment
Two patient
was selected
was used
[DOI] 10.1016/j.jaut.2020.102537 PMC 바로가기 [Article Type] Article
[DOI] 10.1016/j.jaut.2020.102537 PMC 바로가기 [Article Type] Article